CL2015000897A1 - Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer. - Google Patents

Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.

Info

Publication number
CL2015000897A1
CL2015000897A1 CL2015000897A CL2015000897A CL2015000897A1 CL 2015000897 A1 CL2015000897 A1 CL 2015000897A1 CL 2015000897 A CL2015000897 A CL 2015000897A CL 2015000897 A CL2015000897 A CL 2015000897A CL 2015000897 A1 CL2015000897 A1 CL 2015000897A1
Authority
CL
Chile
Prior art keywords
cancer
hemoglobin
prevention
treatment
pharmaceutical composition
Prior art date
Application number
CL2015000897A
Other languages
English (en)
Spanish (es)
Inventor
Bing Lou Wong
Norman Fung Man Wai
Sui Yi Kwok
Sze Hang Lau
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of CL2015000897A1 publication Critical patent/CL2015000897A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015000897A 2012-10-12 2015-04-09 Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer. CL2015000897A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (1)

Publication Number Publication Date
CL2015000897A1 true CL2015000897A1 (es) 2015-08-21

Family

ID=50475529

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000897A CL2015000897A1 (es) 2012-10-12 2015-04-09 Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.

Country Status (21)

Country Link
US (2) US20140106004A1 (https=)
EP (1) EP2906222A4 (https=)
JP (1) JP6113850B2 (https=)
KR (1) KR20150065881A (https=)
CN (1) CN104717966B (https=)
AP (1) AP2015008315A0 (https=)
AR (1) AR093023A1 (https=)
AU (1) AU2013329121B2 (https=)
BR (1) BR112015007475A2 (https=)
CA (1) CA2884521C (https=)
CL (1) CL2015000897A1 (https=)
EA (1) EA201500301A1 (https=)
IL (1) IL237763A (https=)
MA (1) MA37994A2 (https=)
MX (1) MX367562B (https=)
PH (1) PH12015500562B1 (https=)
SG (3) SG10201608747RA (https=)
TW (1) TW201414489A (https=)
UY (1) UY35082A (https=)
WO (1) WO2014059199A1 (https=)
ZA (1) ZA201501949B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
KR102854338B1 (ko) 2017-06-26 2025-09-03 루넬라 바이오테크 인코포레이티드 미토케토신: 암 세포에서 케톤 대사를 표적화하는 미토콘드리아-기반의 치료제
JPWO2019124423A1 (ja) * 2017-12-19 2020-10-22 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び／又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
KR102793996B1 (ko) 2022-03-31 2025-04-09 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119746044A (zh) * 2025-03-06 2025-04-04 润方（北京）生物医药研究院有限公司 血红蛋白氧载体在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
NO2440239T3 (https=) * 2009-06-09 2018-02-10
EP2451459B1 (en) * 2009-07-07 2017-11-22 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
JP2015534946A (ja) 2015-12-07
AU2013329121A1 (en) 2015-04-09
PH12015500562A1 (en) 2015-05-04
US9056098B2 (en) 2015-06-16
ZA201501949B (en) 2016-01-27
SG11201502133SA (en) 2015-04-29
BR112015007475A2 (pt) 2017-08-08
US20140106004A1 (en) 2014-04-17
SG10201608747RA (en) 2016-12-29
JP6113850B2 (ja) 2017-04-12
WO2014059199A8 (en) 2014-05-30
IL237763A (en) 2017-07-31
CN104717966A (zh) 2015-06-17
CA2884521C (en) 2018-05-01
MX2015004512A (es) 2015-12-01
EA201500301A1 (ru) 2015-08-31
EP2906222A4 (en) 2016-06-22
MX367562B (es) 2019-08-27
PH12015500562B1 (en) 2015-05-04
TW201414489A (zh) 2014-04-16
HK1206281A1 (en) 2016-01-08
EP2906222A1 (en) 2015-08-19
SG10201607846PA (en) 2016-11-29
CA2884521A1 (en) 2014-04-17
US20140303085A1 (en) 2014-10-09
UY35082A (es) 2014-07-31
MA37994A2 (fr) 2016-06-30
AR093023A1 (es) 2015-05-13
AU2013329121B2 (en) 2017-05-25
AP2015008315A0 (en) 2015-03-31
CN104717966B (zh) 2018-08-24
KR20150065881A (ko) 2015-06-15
WO2014059199A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
MX2015011713A (es) Compuestos para el tratamiento de cancer.
IL234989B (en) Compounds and compositions thereof for treating cancer
CR20150316A (es) Compuestos y sus métodos de empleo
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
MX382017B (es) Metodos para el tratamiento de cancer pancreatico.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
CL2015001250A1 (es) Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros.
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX375926B (es) Compuestos y metodos para inhibir el transporte de fosfato.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
CL2015002591A1 (es) Entidades químicas.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
IL225442A0 (en) Compositions comprising rankl inhibitors for use in treating and preventing cancer